Search Results
1
Study Matches
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW)
for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate
at Week 24.
Suzanne Van Landingham
All
18 Years and over
Phase 3
NCT05517421
Thyroid Eye Disease, Eye Abnormalities [C11], Thyroid Diseases [C19], Other, Eye & Vision, Plastic & Reconstructive Surgery